Birdwatch Note
2024-02-06 00:38:51 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a neurologic disease with dysfunction of the immune, endocrine, cardiovascular and metabolic systems. The disease has a lower quality of life on average than MS, chronic kidney failure, or congestive heart failure. https://www.mayoclinicproceedings.org/article/S0025-6196(23)00402-0/fulltext
Written by 0A20BC45A44EB62CB363343297CCC67B9DD477674A608FA75CEA11A7AE82E6F2
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1754632271284387879
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1754665926249869420
- noteId - 1754665926249869420
- participantId -
- noteAuthorParticipantId - 0A20BC45A44EB62CB363343297CCC67B9DD477674A608FA75CEA11A7AE82E6F2 Participant Details
- createdAtMillis - 1707179931590
- tweetId - 1754632271284387879
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a neurologic disease with dysfunction of the immune, endocrine, cardiovascular and metabolic systems. The disease has a lower quality of life on average than MS, chronic kidney failure, or congestive heart failure. https://www.mayoclinicproceedings.org/article/S0025-6196(23)00402-0/fulltext
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-02-06 00:38:51 UTC (1707179931590) |
2024-02-06 14:28:52 UTC (1707229732929) |
CURRENTLY_RATED_HELPFUL | 2024-02-07 00:47:28 UTC (1707266848650) |
CURRENTLY_RATED_HELPFUL | 2024-02-06 14:28:52 UTC (1707229732929) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-02-06 01:28:15 -0600 | Rating Details | |
| 2024-02-06 01:23:43 -0600 | Rating Details | |
| 2024-02-06 00:56:56 -0600 | Rating Details | |
| 2024-02-06 00:24:51 -0600 | Rating Details | |
| 2024-02-06 00:19:32 -0600 | Rating Details | |
| 2024-02-05 23:52:23 -0600 | Rating Details | |
| 2024-02-05 23:29:16 -0600 | Rating Details | |
| 2024-02-05 23:27:53 -0600 | Rating Details | |
| 2024-02-05 22:43:14 -0600 | Rating Details | |
| 2024-02-05 22:19:35 -0600 | Rating Details | |
| 2024-02-05 22:16:16 -0600 | Rating Details | |
| 2024-02-05 22:00:30 -0600 | Rating Details | |
| 2024-02-05 21:59:30 -0600 | Rating Details | |
| 2024-02-05 21:43:38 -0600 | Rating Details | |
| 2024-02-05 21:42:40 -0600 | Rating Details | |
| 2024-02-05 21:28:57 -0600 | Rating Details | |
| 2024-02-05 21:13:34 -0600 | Rating Details | |
| 2024-02-05 21:06:27 -0600 | Rating Details | |
| 2024-02-05 21:01:17 -0600 | Rating Details | |
| 2024-02-05 20:55:59 -0600 | Rating Details | |
| 2024-02-05 20:42:00 -0600 | Rating Details | |
| 2024-02-05 20:41:11 -0600 | Rating Details | |
| 2024-02-05 20:33:05 -0600 | Rating Details | |
| 2024-02-05 20:28:05 -0600 | Rating Details | |
| 2024-02-05 20:26:32 -0600 | Rating Details | |
| 2024-02-05 20:23:14 -0600 | Rating Details | |
| 2024-02-05 20:18:15 -0600 | Rating Details | |
| 2024-02-05 19:13:33 -0600 | Rating Details | |
| 2024-02-05 19:12:27 -0600 | Rating Details | |
| 2024-02-05 19:10:21 -0600 | Rating Details | |
| 2024-02-05 19:02:41 -0600 | Rating Details | |
| 2024-02-05 19:02:02 -0600 | Rating Details | |
| 2024-02-05 18:59:30 -0600 | Rating Details | |
| 2024-02-05 18:57:14 -0600 | Rating Details | |
| 2024-02-05 18:46:07 -0600 | Rating Details | |
| 2024-02-05 18:44:46 -0600 | Rating Details | |
| 2024-02-05 18:43:05 -0600 | Rating Details | |
| 2024-02-06 17:16:08 -0600 | Rating Details | |
| 2024-02-06 16:31:52 -0600 | Rating Details | |
| 2024-02-06 13:42:53 -0600 | Rating Details | |
| 2024-02-06 13:26:18 -0600 | Rating Details | |
| 2024-02-06 13:22:40 -0600 | Rating Details | |
| 2024-02-06 13:04:49 -0600 | Rating Details | |
| 2024-02-06 12:29:31 -0600 | Rating Details | |
| 2024-02-06 12:07:13 -0600 | Rating Details | |
| 2024-02-06 11:12:36 -0600 | Rating Details | |
| 2024-02-06 10:50:30 -0600 | Rating Details | |
| 2024-02-06 10:02:46 -0600 | Rating Details | |
| 2024-02-06 09:55:52 -0600 | Rating Details | |
| 2024-02-06 09:36:53 -0600 | Rating Details | |
| 2024-02-06 09:33:50 -0600 | Rating Details | |
| 2024-02-06 09:24:58 -0600 | Rating Details | |
| 2024-02-06 09:13:05 -0600 | Rating Details | |
| 2024-02-06 09:05:54 -0600 | Rating Details | |
| 2024-02-06 09:02:50 -0600 | Rating Details | |
| 2024-02-06 08:51:46 -0600 | Rating Details | |
| 2024-02-06 08:50:40 -0600 | Rating Details | |
| 2024-02-06 08:46:45 -0600 | Rating Details | |
| 2024-02-06 08:16:41 -0600 | Rating Details | |
| 2024-02-06 07:15:16 -0600 | Rating Details | |
| 2024-02-06 07:13:22 -0600 | Rating Details | |
| 2024-02-06 06:33:55 -0600 | Rating Details | |
| 2024-02-06 05:42:59 -0600 | Rating Details | |
| 2024-02-06 05:33:05 -0600 | Rating Details | |
| 2024-02-06 05:16:32 -0600 | Rating Details | |
| 2024-02-06 04:48:42 -0600 | Rating Details | |
| 2024-02-06 03:51:06 -0600 | Rating Details | |
| 2024-02-06 03:31:08 -0600 | Rating Details | |
| 2024-02-06 03:06:58 -0600 | Rating Details | |
| 2024-02-06 02:55:57 -0600 | Rating Details | |
| 2024-02-06 02:54:02 -0600 | Rating Details | |
| 2024-02-06 02:49:54 -0600 | Rating Details | |
| 2024-02-06 01:56:54 -0600 | Rating Details | |
| 2024-02-06 01:44:55 -0600 | Rating Details | |
| 2024-02-06 01:35:17 -0600 | Rating Details | |
| 2024-02-06 01:32:54 -0600 | Rating Details | |
| 2024-02-07 09:43:33 -0600 | Rating Details | |
| 2024-02-07 08:15:06 -0600 | Rating Details | |
| 2024-02-07 05:10:02 -0600 | Rating Details | |
| 2024-02-06 23:58:52 -0600 | Rating Details | |
| 2024-02-06 18:14:23 -0600 | Rating Details | |
| 2024-02-09 15:04:10 -0600 | Rating Details | |
| 2024-02-10 07:57:06 -0600 | Rating Details | |
| 2024-02-11 04:55:40 -0600 | Rating Details | |
| 2024-02-07 05:20:34 -0600 | Rating Details | |
| 2024-02-13 08:03:54 -0600 | Rating Details | |
| 2024-02-07 13:41:31 -0600 | Rating Details | |
| 2024-02-07 04:53:36 -0600 | Rating Details | |
| 2024-02-07 04:07:41 -0600 | Rating Details | |
| 2024-02-07 01:47:08 -0600 | Rating Details | |
| 2024-02-06 20:51:37 -0600 | Rating Details | |
| 2024-02-06 20:02:23 -0600 | Rating Details | |
| 2024-02-06 18:34:18 -0600 | Rating Details | |
| 2024-02-06 14:31:12 -0600 | Rating Details | |
| 2024-02-06 12:12:48 -0600 | Rating Details | |
| 2024-02-06 10:30:26 -0600 | Rating Details | |
| 2024-02-06 10:04:49 -0600 | Rating Details | |
| 2024-02-06 09:59:07 -0600 | Rating Details | |
| 2024-02-06 09:48:21 -0600 | Rating Details | |
| 2024-02-06 09:23:06 -0600 | Rating Details | |
| 2024-02-06 09:18:44 -0600 | Rating Details | |
| 2024-02-06 08:55:09 -0600 | Rating Details | |
| 2024-02-06 07:26:21 -0600 | Rating Details | |
| 2024-02-06 06:56:24 -0600 | Rating Details | |
| 2024-02-06 06:08:18 -0600 | Rating Details | |
| 2024-02-06 05:53:19 -0600 | Rating Details | |
| 2024-02-06 04:53:35 -0600 | Rating Details | |
| 2024-02-06 03:02:15 -0600 | Rating Details | |
| 2024-02-06 02:20:31 -0600 | Rating Details | |
| 2024-02-06 02:20:01 -0600 | Rating Details | |
| 2024-02-06 02:13:31 -0600 | Rating Details | |
| 2024-02-06 01:49:01 -0600 | Rating Details | |
| 2024-02-06 00:56:06 -0600 | Rating Details | |
| 2024-02-06 00:06:44 -0600 | Rating Details | |
| 2024-02-05 23:55:08 -0600 | Rating Details | |
| 2024-02-05 23:42:17 -0600 | Rating Details | |
| 2024-02-05 23:37:07 -0600 | Rating Details | |
| 2024-02-05 23:10:32 -0600 | Rating Details | |
| 2024-02-05 21:53:59 -0600 | Rating Details | |
| 2024-02-05 21:06:32 -0600 | Rating Details | |
| 2024-02-05 21:06:19 -0600 | Rating Details | |
| 2024-02-05 21:01:34 -0600 | Rating Details | |
| 2024-02-05 20:37:49 -0600 | Rating Details | |
| 2024-02-05 20:18:19 -0600 | Rating Details | |
| 2024-02-05 20:09:27 -0600 | Rating Details | |
| 2024-02-05 20:01:12 -0600 | Rating Details | |
| 2024-02-05 19:47:46 -0600 | Rating Details | |
| 2024-02-05 19:09:27 -0600 | Rating Details | |
| 2024-02-05 18:58:18 -0600 | Rating Details | |
| 2024-02-05 18:42:25 -0600 | Rating Details | |
| 2024-02-05 18:41:34 -0600 | Rating Details | |
| 2024-04-09 14:22:50 -0500 | Rating Details |